Biology Reference
In-Depth Information
Demmler GJ (1996) Congenital cytomegalovirus infection and disease. Adv Pediatr Infect Dis
11:135-162
Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, Khanna R (2003) Ex vivo
profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific
reactivities in healthy virus carriers. J Virol 77:5226-5240
Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C, Pincus S, Rodeck U, Meric C, Plotkin
SA, Gonczol E (1999) Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-
specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte
responses by naked DNA immunization. Vaccine 17:50-58
Evans TG, Wloch M, Hermanson G, Selinsky C, Geall A, Kaslow D (2004) Phase 1 trial of a
bivalent, formulated plasmid DNA CMV vaccine for use in the transplant population. Abstracts
of the 44
th
ICAAC; G-543
Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA (1992) The outcome of congenital
cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663-667
Fowler KB, Stagno S, Pass RF (2003) Maternal immunity and prevention of congenital cytomega-
lovirus infection. JAMA 289:1008-1011
Fowler KB, Stagno S, Pass RF (2004) Interval between births and risk of congenital cytomegalo-
virus infection. Clin Infect Dis 38:1035-1037
Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi
S, Burke RL, Duliege AM (1999) Effects of antigen dose and immunization regimens on anti-
body responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis
180:1700-1703
Gopal IN, Quinn A, Henry SC, Hamilton JD, Staats HF, Frothingham R (2005) Nasal peptide
vaccination elicits CD8 responses and reduces viral burden after challenge with virulent
murine cytomegalovirus. Microbiol Immunol 49:113-119
Griffiths PD, McLean A, Emery VC (2001) Encouraging prospects for immunisation against pri-
mary cytomegalovirus infection. Vaccine 19:1356-1362
Hardy CM (2007) Current status of virally vectored immunocontraception for biological control
of mice. Soc Reprod Fertil Suppl 63:495-506
Heineman TC, Schleiss M, Bernstein DI, Spaete RR, Yan L, Duke G, Prichard M, Wang Z, Yan
Q, Sharp MA, Klein N, Arvin AM, Kemble G (2006) A phase 1 study of 4 live, recombinant
human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193:1350-1360
Ishibashi K, Tokumoto T, Tanabe K, Shirakawa H, Hashimoto K, Kushida N, Yanagida T, Inoue
N, Yamaguchi O, Toma H, Suzutani T (2007) Association of the outcome of renal transplanta-
tion with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin
Infect Dis 45:60-67
Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R,
Adler SP (2006a) Antigen-specific T cell responses induced by Towne cytomegalovirus
(CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 35:332-337
Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R,
Girling V, Adler SP (2006b) Safety and immunogenicity of Towne cytomegalovirus vaccine
with or without adjuvant recombinant interleukin-12. Vaccine 24:5311-5319
Khanna R, Diamond DJ (2006) Human cytomegalovirus vaccine: time to look for alternative
options. Trends Mol Med 12:26-33
Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W,
Pass RF, Kiell JM, Soong SJ, Whitley RJ; National Institute of Allergy and Infectious Diseases
Collaborative Antiviral Study Group (2003) Effect of ganciclovir therapy on hearing in symp-
tomatic congenital cytomegalovirus disease involving the central nervous system: a rand-
omized, controlled trial. J Pediatr 143:16-25
Maschmann J, Hamprecht K, Dietz K, Jahn G, Speer CP (2001) Cytomegalovirus infection of
extremely low-birth weight infants via breast milk. Clin Infect Dis 33:1998-2003
McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell
SR (1994) Identification of the major late human cytomegalovirus matrix protein pp65 as a
target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103-110
